Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (January 2022)
25 slides from Sutro Biopharma's investor presentation, Jan 10, 2022
Slide 1: Company Overview January 2022
NON-CONFIDENTIAL Company Overview January 2022 Sutro Biopharma NASDAQ: STRO Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Drug Discovery Platform Enables the Potential for Best-in-Class Molecules
Drug Discovery Platform Enables the Potential for Best-in-Class Molecules Precise novel design to enhance efficacy and safety across multiple modalities and targets Enhanced tumor targeting of cytotoxic payloads Bispecific ADC ISAC: Immune- stimulating ADC: targeting novel payloads Bispecific Antibo
Slide 4: Robust Pipeline through Wholly-Owned and Partnered Programs
Robust Pipeline through Wholly-Owned and Partnered Programs Four product candidates advancing in the clinic and late-stage discovery programs Modality Program Target Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Antibody-Drug Conjugate STRO-002 FolRα ADC Ovarian Cancer Ovarian Cancer
Slide 5: Achievements and Milestones
Achievements and Milestones Clinical data readouts and partnerships provide multiple 2022 value drivers for Sutro STRO-002, FolRα ADC Greater China deal with Tasly (Dec. 2021) Ovarian cancer dose-expansion interim data (Jan. 2022) Dose-expansion data with durability at a scientific meeting (2H 2022)
Slide 6: FolRα-Targeting ADC: Potential Best-in-Class ADC for Ovarian Cancer
NON-CONFIDENTIAL FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian Cancer STRO 002
Slide 7: STRO-002 Highly optimized ADC designed to drive efficient tumor responses
STRO 002 Highly optimized ADC designed to drive efficient tumor responses across a broad range of target antigen levels 1 Sutro-proprietary tubulin-targeting 3-aminophenol hemiasterlin warhead, SC209 2 Based on STRO-002 pre-clinical models showing immune stimulation at site of tumor upon cell death
Slide 8: STRO-002 Phase 1 Study in Patients with Advanced Ovarian Cancer
STRO 002 Phase 1 Study in Patients with Advanced Ovarian Cancer Two-part design to explore safety, anti-tumor activity, dosing, and FolRα enrichment strategy Protocol Baseline Characteristics Inclusive of all FolRα expression levels; tissue samples voluntary and samples received from <50% of patient
Slide 9: Patient Characteristics in Dose Expansion Cohort
Dose Expansion STRO 002 Patient Characteristics in Dose Expansion Cohort Interim data for dose expansion are as of November 8, 2021 Patients Randomized & Dosed Safety Evaluable (as of Nov 8, 2021) N=43 RECIST v1.1 Evaluable One Post-Baseline Scan N=33 Not Yet Evaluable No Post Baseline Scan N=8 Disc
Slide 10: Maximum Change in Tumor Target Lesions (N=33)
20% -30% 2 pts had 0% Δ Maximum Change in Tumor Target Lesions (N=33) Partial Response 4.3 mg/kg 5.2 mg/kg Treatment ongoing as of Nov 8, 2021 PR confirmed by next scheduled scan (after Nov. 8, 2021) Dose Expansion STRO 002 Dose Response Demonstrated Interim data suggest that 5.2 mg/kg starting dose
Slide 11: Objective Response by RECIST v1.1
Starting Dose Best Overall Response (BOR) 4.3 mg/kg 5.2 mg/kg All Comers Evaluable patients N=16 N=17 N=33 PR 3 4 7 PR confirmed by next scheduled scan post Nov. 8, 2021 0 4 4 Total PR 3 8 11 ORR (%) 18.8% 47.1% 33.3% SD 10 4 14 PD 3 5 8 Dose Expansion STRO 002 Objective Response by RECIST v1.1 33%
Slide 12: Robust Anti-tumor Activity and Disease Control Demonstrated
Dose Expansion STRO 002 Robust Anti-tumor Activity and Disease Control Demonstrated Responders experienced rapid tumor reduction or a steady deepening of response Change from baseline (%) Weeks since first treatment 20 -30 -100 0 Change in Sum of Diameters for Target Lesions Over Time (N=33) Startin
Slide 13: Encouraging Response Rates and Preliminary Data on Durability
Encouraging Response Rates and Preliminary Data on Durability Interim data suggest initiating with 5.2 mg/kg followed by a dose adjustment Treatment Duration on Patients with at Least One Dose (N=43) Dose Expansion STRO 002 Initial data show partial responses confirmed & maintained following dose ad
Slide 14: Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level
Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level Ongoing Partial Response with 72% reduction in tumor burden Dose Expansion STRO 002 Initial diagnosis: Stage IV ovarian cancer, Jan 2020 3 Prior Regimens: Resistant to 1st Neoadjuvant / adjuvant Carbo / Taxol / Taxotere Refrac
Slide 15: Patients at 5.2 mg/kg and TPS > 25% demonstrated 53.8% ORR
Patients at the 5.2 mg/kg starting dose and TPS > 25% demonstrated 53.8% ORR (n=13) ORR by TPS Expression Levels (Total Samples N=33) Dose Expansion STRO 002 TPS Overall TPS ≤ 25% TPS > 25% TPS > 50% TPS > 75% ORR 33.3% 12.5% 40.0% 42.1% 43.8% Number of patient samples N=33 N=8 N=25 N=19 N=16 PR(1)
Slide 16: Emerging Safety Profile is Manageable
Emerging Safety Profile is Manageable – 85.5% of TEAEs were Grade 1-2 No new safety signals were observed, including the absence of keratopathy 4.3 mg/Kg (N=23) 5.2 mg/Kg (N=20) Total (N=43) Grade 3 n (%) Grade 4 n (%) Grade 5 n (%) Grade 3 n (%) Grade 4 n (%) Grade 5 n (%) Grade 3 n (%) Grade 4 n (
Slide 17: Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy
Patients at the 5.2 mg/kg starting dose and TPS > 25% demonstrated 53.8% ORR (7/13) Dose Expansion STRO 002 Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy Emerging data inform potential starting dose and enrichment strategy Total of 11 confirmed PR (1) out of 33 RECIST v
Slide 18: Progressing & Expanding the STRO-002 Franchise
Dose-escalation cohort 39 patients, enrollment completed August 2020 Dose-expansion cohort 44 patients enrolled in US and Spain sites, enrollment completed November 2021 Combo study with bevacizumab Trial is open and enrolling patients FPI planned for early 2022 Registration-directed trial Pending F
Slide 19: CD74-Targeting ADC: Potential First and Best-in-Class ADC for B-Cell Malignancies
NON-CONFIDENTIAL CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies STRO 001
Slide 20: STRO-001 Potential First-in-Class Molecule for Patients with NHL and MM
1 STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: Comprises two non-cleavable linker-warheads that are stable in circulation CD74 F404 pAMF 2 3 Non-cleavable linker CD74 is expressed in many hematological cancers and rapidly internalized
Slide 21: STRO-001 Dose Escalation Study NHL Cohort Update at ASH 2020
R/R multiple myeloma (N=30) R/R NHL (N=30) Cohort A Cohort B RP2D RP2D STRO-001-BCM1 Dose Escalation Study NHL Cohort Update at ASH 2020 A total of 21 patients have been treated with STRO-001 and 18 patients were evaluable for response as of October 30, 2020 Dose range 0.05-2.5 mg/kg and MTD has not
Slide 22: Baseline Characteristics and TEAEs
Baseline Characteristic (N=21) Age, median (range), years 64.5 (21–82) Time from diagnosis, median (range), years 6.0 (1.0–29.8) NHL subtype, n (%) 21 (100) DLBCL 7 (33) Follicular lymphoma 7 (33) MCL 2 (10) Marginal zone lymphoma 2 (10) Burkitt’s Lymphoma 1 (5) Composite DLBCL/FL 1 (5) Composite DL
Slide 23: Responses to STRO-001 Treatment
Responses to STRO-001 Treatment Duration Best Response Patients, n STRO-001 Dose NHL subtype CR 1 0.075 mg/kg DLBCL PR 2 0.65, 1.27 mg/kg DLBCL SD 3 1.27, 1.78, 2.5 mg/kg Marginal Zone and Follicular PD 12 Multiple Encouraging Interim Treatment Duration and Responses Partial responses in two DLBCL p
Slide 24: Financial Overview
$254.2M in cash, cash equivalents & marketable securities as of Sept. 30, 2021 Projected cash runway into 2H 2023(1), based on current business plans and assumptions ~1.6M shares of Vaxcyte (Nasdaq: PCVX) not included in the above reported cash Funding received from our collaborators of ~$434M throu
Slide 25: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Chief Executive Officer and Member of the Board of Directors Trevor Hallam, PhD President of Research and Chief Scientific Officer Arturo Molina, MD, MS, FACP Chief Medical Officer Ed Albini, MBA Chief Financial Officer Shabbir Anik, PhD Chief Technical
Sutro Biopharma — Investor Presentation (January 2022) on 6ix